Cargando…

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

BACKGROUND: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-naïv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhee, Soo-Yon, Schapiro, Jonathan M., Saladini, Francesco, Zazzi, Maurizio, Khoo, Saye, Shafer, Robert W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903540/ https://www.ncbi.nlm.nih.gov/pubmed/36750835 http://dx.doi.org/10.1186/s12981-023-00503-5

Ejemplares similares

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2021)

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
por: Bennett, Diane E., et al.
Publicado: (2009)

The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance
por: Gifford, Robert J., et al.
Publicado: (2009)

HIV‐1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates
por: Rhee, Soo‐Yon, et al.
Publicado: (2020)

Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis
por: Avila-Rios, Santiago, et al.
Publicado: (2016)

Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect
por: De Luca, Andrea, et al.
Publicado: (2015)

Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network)
por: Rossetti, Barbara, et al.
Publicado: (2023)

Genetic Variability of HIV-1 for Drug Resistance Assay Development
por: Clutter, Dana S., et al.
Publicado: (2016)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
por: Picarazzi, Francesca, et al.
Publicado: (2020)

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
por: Rock, Alexander E, et al.
Publicado: (2020)

More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1
por: Feder, Alison F, et al.
Publicado: (2016)

Correction: More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1
por: Feder, Alison F, et al.
Publicado: (2017)

Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance
por: Clutter, Dana S., et al.
Publicado: (2016)

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
por: Seden, Kay, et al.
Publicado: (2017)

Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates
por: Asante-Appiah, Ernest, et al.
Publicado: (2021)

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

The global burden of HIV-1 drug resistance in the past 20 years
por: Zazzi, Maurizio, et al.
Publicado: (2018)

Geographically-stratified HIV-1 group M pol subtype and circulating recombinant form sequences
por: Rhee, Soo-Yon, et al.
Publicado: (2018)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
por: Zizioli, Daniela, et al.
Publicado: (2023)

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa
por: Steegen, Kim, et al.
Publicado: (2021)

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
por: Blanco, Jose-Luis, et al.
Publicado: (2011)

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
por: Reuman, Elizabeth C., et al.
Publicado: (2010)

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study
por: Mazzitelli, Maria, et al.
Publicado: (2022)

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen
por: Tsai, Hung-Chin, et al.
Publicado: (2022)

Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana
por: Bareng, Ontlametse T., et al.
Publicado: (2022)

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population
por: Rhee, Soo-Yon, et al.
Publicado: (2019)

Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism
por: Meini, Genny, et al.
Publicado: (2013)

1011. Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1
por: Mills, Anthony, et al.
Publicado: (2020)

The changing face of HIV resistance; HIV drug resistance north and south — what's next?
por: Schapiro, J
Publicado: (2010)

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
por: Molina, Jean-Michel, et al.
Publicado: (2022)

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions
por: Khalilieh, Sauzanne, et al.
Publicado: (2020)

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection
por: Pham, Hanh Thi, et al.
Publicado: (2020)

Changes in weight and BMI with first-line doravirine-based therapy
por: Orkin, Chloe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4l2i0qmr6hokjdu14l6q18l9e7